Latest News

Pharmacists can educate patients on preventive measures to avoid heat-related illnesses.

Educate patients about psoriasis pharmacotherapy options and monitor for medication adherence

The designation highlights an emerging strategy targeting TNFR2-mediated immune suppression in heavily pretreated platinum-resistant ovarian cancer.

Early trial data suggest zongertinib shrinks HER2‑mutant NSCLC brain metastases, highlighting CNS control and pharmacist guidance.

IRA reshapes Medicare drug costs: Part B negotiations loom, pharmacies adapt, and patients gain Part D caps—see impacts on oncology care and access.

New recommendations move noncore shots to shared clinical decision-making, but a court stay keeps day-to-day pharmacy practice unchanged.

A phase 4 study found that a suzetrigine-based multimodal pain regimen provided favorable postoperative pain control, with 76.1% of patients recovering without opioid rescue medication.

A first-in-class RNA degrader targeting MYC mRNA showed preclinical antimyeloma activity, offering a potential new strategy for targeting a historically difficult-to-drug driver of multiple myeloma.

Incrementalism is out of favor, and a wholesale move toward professional judgment is underway.

Oncology pharmacists unite care teams like World Cup midfielders—coordinating safe care and supporting patients through hope, setbacks, and dignity.

NICE’s family history–based referral criteria identified just 4.4% of women under 50 who developed breast cancer within 10 years.

A 61,000-woman Danish cohort found overweight or obesity trajectories from 6 years of age tracked with lower odds of childbirth by the mid-20s.

Integrated access to the state immunization registry helped a Discount Drug Mart pharmacist avoid an unnecessary pneumococcal vaccine and strengthen patient trust.

Jerry P. Abraham, MD, MPH, CMQ, discusses the persistent risks of COVID-19 and how a newly approved postexposure prophylaxis option is reshaping pharmacists' role in prevention.

A US claims analysis found a 32% relative reduction in major adverse cardiovascular events (MACE) with tirzepatide vs a placebo-proxy comparator.

Every additional access point—a pharmacist trained to screen, counsel, and, where authorized, initiate or manage therapy—is a smaller referral bottleneck.

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

Pharmacists can guide patients in verifying sources, identifying licensed pharmacies, and understanding compounded vs FDA-approved products.

A new study found that first-prescription buprenorphine abandonment nearly doubled from 2020 to 2024.

A revamped weight management program adds transparent Zepbound and Foundayo pricing, $29 MinuteClinic visits, and pharmacist support at 9000 sites.

Phase 3 SOLARIS shows high-dose vitamin D3 with first-line chemo in metastatic colorectal cancer is safe—but does not significantly improve PFS.